PDCD1 and cancer: The in vivo experiments showed that the EZM2302 treatment could increase the infiltration of CD8+ T cells, NK cells and DCs (Fig. 5M), which indicate that EZM2302 may have synergistic effect with anti PD-1 Ab to improve the anti-tumor response in murine cancer models.